Navin Fluorine Schedules Investor Meet for June 02
Navin Fluorine International Limited announced an analyst and institutional investor meet for June 02, 2026, under Regulation 30. The company recently posted strong Q4 FY26 results with net profit rising 124% to ₹212.62 crore and revenue increasing 34% to ₹937.71 crore. For the full year FY26, net profit grew 130% to ₹663.56 crore, supported by robust performance across its HPP, Specialty Chemicals, and CDMO segments.
*this image is generated using AI for illustrative purposes only.
Navin Fluorine International Limited has announced an interaction with analysts and institutional investors scheduled for June 02, 2026. The meeting will be conducted physically as part of the Axis Capital Rising Stars Conference and will include both one-on-one and group meetings. The discussions will be based on publicly available information.
Recent Financial Performance
The company recently reported its financial results for the quarter and fiscal year ended March 31, 2026. For Q4 FY26, the net profit surged 124% year-on-year to ₹212.62 crore, compared to ₹94.98 crore in the same period last year. Revenue from operations for the quarter increased by 34% to ₹937.71 crore. Operating EBITDA for the quarter stood at ₹321.15 crore, an 80% jump from ₹178.71 crore in Q4 FY25, with the margin expanding by 875 basis points to 34.2%.
Annual Highlights
For the full fiscal year FY26, the company reported a 130% increase in net profit to ₹663.56 crore. Consolidated revenue for the year reached ₹3,313.90 crore, up 41% from ₹2,349.38 crore in FY25. Operating EBITDA grew 103% to ₹1,081.68 crore. The growth was broad-based across business verticals, with the Hydrofluorocarbon Products (HPP) segment growing by 34%, and the Specialty Chemicals and Contract Development and Manufacturing Organization (CDMO) segments reporting growth of 44% and 59% respectively.
Capital Expenditure Plans
The company is actively investing in capacity expansion. Key projects include additional HFC capacity equivalent to 15,000 MTPA of R32, involving a capex of ₹236.5 crore, expected to be commissioned by Q3FY27. De-bottlenecking MPP capacity at Dahej, with a capex of ₹75 crore, is also targeted for commissioning by Q3FY27. Additionally, an advanced materials project with a capex of ₹120 crore is slated for commissioning by Q1FY27.
Financial Metrics
| Metric | Q4 FY26 | Q4 FY25 | YoY Change | FY26 | FY25 | YoY Change |
|---|---|---|---|---|---|---|
| Net Revenue from Operations (₹ Crs.) | 937.71 | 700.94 | 34% | 3,313.90 | 2,349.38 | 41% |
| Operating EBITDA (₹ Crs.) | 321.15 | 178.71 | 80% | 1,081.68 | 533.72 | 103% |
| Operating EBITDA Margin | 34.2% | 25.5% | 875 Bps | 32.6% | 22.7% | 992 Bps |
| Net Profit (₹ Crs.) | 212.62 | 94.98 | 124% | 663.56 | 288.60 | 130% |
Historical Stock Returns for Navin Fluorine International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.18% | +3.17% | +10.17% | +19.24% | +65.18% | +123.62% |
How might the commissioning of the additional 15,000 MTPA HFC capacity in Q3FY27 impact Navin Fluorine's market share amid evolving global refrigerant phase-down regulations under the Kigali Amendment?
Given the CDMO segment's 59% growth in FY26, which therapeutic areas or multinational pharma partnerships could drive the next phase of expansion for this high-margin business vertical?
With EBITDA margins expanding nearly 1,000 basis points year-on-year, what are the key risks—such as raw material price volatility or Chinese competition—that could compress margins in FY27?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
